Thrombocytopenic Purpura in Childhood

Maria C.  Bouw; Natasja Dors; Heleen van Ommen; Nicole L. Ramakers-Van Woerden

doi:10.1002/pbc.22094

Thrombocytopenic Purpura in Childhood

Maria C. Bouw, Natasja Dors, Heleen van Ommen, Nicole L. Ramakers-Van Woerden^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

25 Citations (Scopus)

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disease, especially in childhood, and has a high mortality rate in the absence of appropriate treatment. It is characterised by microangiopathic haemolytic anaemia and consumptive thrombocytopenia. TTP may be difficult to distinguish from haemolytic uraemic syndrome (HUS) because of similar clinical manifestations and laboratory findings. In the past, TTP and HUS have often been considered to represent variable expressions of a single entity. Our increased understanding of the pathogenesis of TTP has in turn resulted in significant improvements in its treatment and outcomes. Several immunomodulating agents are currently being used with variable outcomes. Pediatr Blood Cancer 2009;53:537–542. © 2009 Wiley-Liss, Inc.

Original language	English
Pages (from-to)	537-542
Journal	Pediatric Blood & Cancer
Volume	53
Issue number	4
DOIs	https://doi.org/10.1002/pbc.22094
Publication status	Published - Oct 2009
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.22094

Cite this

@article{bd570bb7491b47918b20ee3f09d4a9d5,

title = "Thrombocytopenic Purpura in Childhood",

abstract = "Thrombotic thrombocytopenic purpura (TTP) is a rare disease, especially in childhood, and has a high mortality rate in the absence of appropriate treatment. It is characterised by microangiopathic haemolytic anaemia and consumptive thrombocytopenia. TTP may be difficult to distinguish from haemolytic uraemic syndrome (HUS) because of similar clinical manifestations and laboratory findings. In the past, TTP and HUS have often been considered to represent variable expressions of a single entity. Our increased understanding of the pathogenesis of TTP has in turn resulted in significant improvements in its treatment and outcomes. Several immunomodulating agents are currently being used with variable outcomes. Pediatr Blood Cancer 2009;53:537–542. {\textcopyright} 2009 Wiley-Liss, Inc.",

author = "Bouw, {Maria C.} and Natasja Dors and {van Ommen}, Heleen and {Ramakers-Van Woerden}, {Nicole L.}",

note = "{\textcopyright} 2009 Wiley-Liss, Inc",

year = "2009",

month = oct,

doi = "10.1002/pbc.22094",

language = "English",

volume = "53",

pages = "537--542",

journal = "Pediatric Blood & Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Thrombocytopenic Purpura in Childhood

AU - Bouw, Maria C.

AU - Dors, Natasja

AU - van Ommen, Heleen

AU - Ramakers-Van Woerden, Nicole L.

PY - 2009/10

Y1 - 2009/10

N2 - Thrombotic thrombocytopenic purpura (TTP) is a rare disease, especially in childhood, and has a high mortality rate in the absence of appropriate treatment. It is characterised by microangiopathic haemolytic anaemia and consumptive thrombocytopenia. TTP may be difficult to distinguish from haemolytic uraemic syndrome (HUS) because of similar clinical manifestations and laboratory findings. In the past, TTP and HUS have often been considered to represent variable expressions of a single entity. Our increased understanding of the pathogenesis of TTP has in turn resulted in significant improvements in its treatment and outcomes. Several immunomodulating agents are currently being used with variable outcomes. Pediatr Blood Cancer 2009;53:537–542. © 2009 Wiley-Liss, Inc.

AB - Thrombotic thrombocytopenic purpura (TTP) is a rare disease, especially in childhood, and has a high mortality rate in the absence of appropriate treatment. It is characterised by microangiopathic haemolytic anaemia and consumptive thrombocytopenia. TTP may be difficult to distinguish from haemolytic uraemic syndrome (HUS) because of similar clinical manifestations and laboratory findings. In the past, TTP and HUS have often been considered to represent variable expressions of a single entity. Our increased understanding of the pathogenesis of TTP has in turn resulted in significant improvements in its treatment and outcomes. Several immunomodulating agents are currently being used with variable outcomes. Pediatr Blood Cancer 2009;53:537–542. © 2009 Wiley-Liss, Inc.

U2 - 10.1002/pbc.22094

DO - 10.1002/pbc.22094

M3 - Review article

C2 - 19544391

SN - 1545-5009

VL - 53

SP - 537

EP - 542

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

IS - 4

ER -

Thrombocytopenic Purpura in Childhood

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this